Verona Pharma Eyes NDA for COPD Drug Based on Positive Phase III Data

[cafead]

via Verona Pharma plans to file a New Drug Application for its chronic obstructive pulmonary disease (COPD) maintenance treatment, nebulized ensifentrine, following positive Phase III data. The drugmaker’s shares jumped 27% in premarket trading Tuesday.

article source